The antihypertensive drug Valsartan and amlodipine tablets developed by CSPC PHARMA (01093) have been approved to conduct clinical trials.
Shiyao Group (01093) announced that the valsartan and amlodipine maleate tablets developed by the group have been approved by the People's Republic of China.
CSPC PHARMA (01093) announced that the group's developed combination of Valsartan and Amlodipine Maleate tablets has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China.
This product is the world's first approved clinical formulation composed of Valsartan and Amlodipine Maleate. Valsartan and Amlodipine are angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB) respectively, both of which are well-defined antihypertensive drugs with rich experience in combination therapy in clinical practice. The approved clinical indication for this product is mild to moderate essential hypertension that cannot be effectively controlled by monotherapy. Compared to monotherapy products for hypertension, this product has clinical development value in terms of effectiveness and safety.
Related Articles
HK Stock Market Move | XPENG-W(09868) falls more than 4%, G7 starting price is 195,800 yuan, further lower than the previous pre-sale price.
HK Stock Market Move | Some concept stocks of innovative drugs are rising, and two departments have issued documents to promote the development of innovative drugs. Citi believes that the sector will usher in multiple catalysts in the second half of the year.
.png)
A-share market opening express | Three major indexes rise and fall differently. Brain-computer interface sector leads in gains.
HK Stock Market Move | XPENG-W(09868) falls more than 4%, G7 starting price is 195,800 yuan, further lower than the previous pre-sale price.
HK Stock Market Move | Some concept stocks of innovative drugs are rising, and two departments have issued documents to promote the development of innovative drugs. Citi believes that the sector will usher in multiple catalysts in the second half of the year.
A-share market opening express | Three major indexes rise and fall differently. Brain-computer interface sector leads in gains.
